Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
Ergebnis 3 von 629
Regulatory toxicology and pharmacology, 2016-10, Vol.80, p.25-31
2016
Volltextzugriff (PDF)

Details

Autor(en) / Beteiligte
Titel
Clinical safety evaluation of marine oil derived from Calanus finmarchicus
Ist Teil von
  • Regulatory toxicology and pharmacology, 2016-10, Vol.80, p.25-31
Ort / Verlag
Netherlands: Elsevier Inc
Erscheinungsjahr
2016
Quelle
MEDLINE
Beschreibungen/Notizen
  • Marine oils are rich in polyunsaturated fatty acids (PUFAs), including docosahexaenoic and eicosapentaenoic acid. These PUFAs are associated with health benefits and additional sustainable sources of marine oils are desirable. One of the source organisms is Calanus finmarchicus, a copepod endemic to the North Atlantic. PUFAs in the lipid fraction of this organism are largely in the form of wax esters. To assess the safety of these wax esters as a source of PUFAs, a randomized, double-blinded, placebo-controlled clinical trial was conducted whereby 64 subjects consumed 2 g Calanus oil in capsule form daily for a period of one year. A group of 53 subjects consumed placebo capsules. At baseline, 6-, and 12-months, series of evaluations were conducted, including: vital signs, clinical chemistry and hematological evaluations, and adverse event reporting. Food intake and physical exercise were controlled by means of a questionnaire. There were no effects on Calanus oil treatment on any of the safety parameters measured. A slight increase in the incidence of eczema was reported in the Calanus oil group, but the response was minor in nature, not statistically significant after controlling for multiple comparisons, and could not be attributed to treatment. •Calanus oil, a marine oil, is rich in polyunsaturated fatty acids, such as DHA and EPA, in the form of wax esters.•No significant adverse events reported in 64 healthy subjects consuming 2 g Calanus oil for 1 year.•Slight increase in incidence of eczema in Calanus oil group, but could not be attributed to treatment.•Calanus oil can be consumed at 2 g/day, providing a source of DHA and EPA, with no adverse health effects.

Weiterführende Literatur

Empfehlungen zum selben Thema automatisch vorgeschlagen von bX